⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Effectiveness of Tixagevimab/Cilgavimab (Evusheld) in AntiCD20 Treated Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder (P8-6.006)

Dominika Šťastná Marta Vachová Pavel Dušek Gregor Fistravec Jiří Drahota Ingrid Menkyová Dana Horáková Eva Havrdová Petra Nytrová

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the effect of tixagevimab/cilgavimab (T/C) on the incidence of COVID-19 in patients with multiple sclerosis (pwMS) and neuromyelitis optica spectrum disorder (pwNMOSD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Šťastná et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677edf https://doi.org/10.1212/wnl.0000000000206499

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic2024 · 2 citations
2Tolerability and Outcomes with Rollout of Tixagevimab-Cilgavimab in Patients with Common Variable Immunodeficiency2024
3Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?2024 · 5 citations
4Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19Early-Phase Clinical Trial · 2023 · 11 citations
5Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study2024